U.S. market Closed. Opens in 2 hours 44 minutes

STOK | Stoke Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 7.06 - 7.49
52 Week Range 7.06 - 17.58
Beta 0.97
Implied Volatility 405.70%
IV Rank 79.81%
Day's Volume 572,399
Average Volume 848,956
Shares Outstanding 54,077,700
Market Cap 389,900,217
Sector Healthcare
Industry Biotechnology
IPO Date 2019-06-19
Valuation
Profitability
Growth
Health
P/E Ratio -4.37
Forward P/E Ratio -3.41
EPS -1.65
1YR Price Target 27.50
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 110
Country USA
Website STOK
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
*Chart delayed
Analyzing fundamentals for STOK we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see STOK Fundamentals page.

Watching at STOK technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on STOK Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙